Drugs / PHV02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06221813 | Jan → Sep 2024 | Nipah virus disease | Public Health Vaccines LLC | Completed | No outcome recorded |
| Phase 1 | NCT05178901 | Jan 2022 → May 2023 | Nipah virus disease | Public Health Vaccines LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHV02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06221813 ↗ |
| Modality | Vaccine | “rVSV-Nipah Virus Vaccine Candidate PHV02” NCT05178901 ↗ |
| Route | Intramuscular | “The vaccine is administered as a single intramuscular injection” NCT05178901 ↗ |